Discover best-in-market prices on clinically preferred products―together with a suite of applications supporting pharmacy operations and analytics, and innovative strategies to address industry initiatives and issues.

Latest ICER Report Looks at the Value of Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is the latest high-profile disease for which the Institute for Clinical and Economic Review (ICER) has constructed a “value framework” for assessing and comparing available drug treatments. In April, ICER issued a comprehensive, 529-page report on targeted immune modulators (TIMs) for RA that covers 14 medicines—all but two biologics, and none biosimilars. […]

Read More

Pharmaceutical M&A: A New Kind of Drug Deal

As more drug companies merge and overtake each other, healthcare facilities and pharmaceutical customers are feeling the squeeze. With fewer companies in the marketplace, competition is limited, driving higher prices and drug scarcity.

Read More

Biosimilars Update: Zarxio

In March 2015, the FDA green-lighted Zarxio, the first biosimilar product to be approved in the United States, signaling some relief from rising drug costs.

Read More

HealthTrust Addressing Pharmacy Leadership Shortage With Unique Residency Program

In 2014, HealthTrust established the nation’s first corporate-based training program for future pharmacy leaders that provides early career exposure to critical business functions, value-based purchasing and the economic realities of modern medicine, including better management of limited healthcare resources.

Read More

Five Drivers of Rising Drug Costs

Supplier consolidation, heightened FDA scrutiny, industry profit-taking and recurring shortages are conspiring to inflate prices on older drugs.

Read More